![]() Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032
Biosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases)... もっと見る
SummaryBiosimilars Market Research Report By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Growth Hormones), By Application (Oncology, Diabetes, Autoimmune Diseases, Chronic Inflammatory Diseases), By End Use (Hospitals, Clinics, Homecare, Research Institutions), By Manufacturing Process (Recombinant DNA Technology, Hybridoma Technology, Transgenic Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2032Market Overview The biosimilars market is predicted to expand from 11.39 (USD Billion) in 2023 to 41.6 (USD Billion) by 2032. The Biosimilars Market CAGR (growth rate) is anticipated to be approximately 15.49% over the forecast period. Several main drivers are driving the biosimilars industry, including an increase in the prevalence of chronic diseases and a growing need for inexpensive biologic treatments. As healthcare costs continue to grow, biosimilars provide a cost-effective alternative that can improve patient access to critical therapies. Regulatory reforms and developments in manufacturing processes also contribute to market growth by streamlining the approval process and improving product quality. The transition to value-based care models stresses the necessity of low-cost treatment choices, making biosimilars a crucial component of the healthcare ecosystem. Market segment insights The Biosimilars Market is expanding rapidly, notably in the Type category, which includes key medicinal goods such as monoclonal antibodies, insulin, erythropoietin, and growth hormones. The Biosimilars Market is growing rapidly, with a valuation of 11.39 USD billion in 2023 and a forecast revenue of 41.6 USD billion by 2032. This expansion can be attributable to rising demand for more cost-effective treatment alternatives across a variety of therapeutic areas, particularly in the Application segment. In the Biosimilars Market, the End Use segment is critical to establishing the landscape of healthcare delivery. By 2023, the total market is predicted to be worth 11.39 billion USD, indicating the industry's strong expansion. Hospitals are a prominent player in this area, as they increasingly use biosimilars to reduce treatment costs and improve patient outcomes. Clinics also make a substantial contribution, catering to a vast patient population seeking cost-effective solutions in a variety of therapeutic fields. The Biosimilars sector was assessed at 11.39 USD billion in 2023, with strong growth projected in the following years as the sector transitions to advanced manufacturing technologies. Within the Manufacturing Process category, technologies such as Recombinant DNA Technology and Hybridoma Technology play critical roles in biosimilar development. Regional insights The Biosimilars Market is expected to grow rapidly across all regions, with North America, Europe, APAC, South America, and MEA contributing significantly to revenue. North America maintains a majority stake worth 5.0 USD billion in 2023 and is expected to grow to 17.5 USD billion by 2032, proving its dominance in the business due to a robust healthcare infrastructure and increased demand for cost-effective therapies. Europe follows closely, with a valuation of 3.5 USD billion in 2023 and a projected growth rate of 13.0 USD billion, owing to favorable regulations and increased acceptance of biosimilars among healthcare professionals. The APAC region is rising, with a value of 2.0 USD billion in 2023 and an expected growth to 8.0 USD billion, demonstrating promise due to growing patient populations and increased healthcare investments. South America and MEA are smaller markets, with valuations of 0.7 USD billion and 0.19 USD billion respectively in 2023, but they offer chances for growth as healthcare systems expand and access to biosimilars improves. The overall Biosimilars Market data reflects a dynamic growth landscape influenced by regional healthcare policies, patient access to medications, and the economic benefits associated with biosimilar therapies. Key players Key Companies in the Biosimilars Market Include Zydus Cadila, Eli Lilly, Samsung Bioepis, GSK, AbbVie, Boehringer Ingelheim, Teva Pharmaceutical Industries, Celltrion, Fresenius Kabi, Amgen, Reddy's Laboratories, Mylan, Sandoz, Pfizer, and Novartis. Table of ContentsTABLE OF CONTENTS1. EXECUTIVE SUMMARY 1.1. MARKET OVERVIEW 1.2. KEY FINDINGS 1.3. MARKET SEGMENTATION 1.4. COMPETITIVE LANDSCAPE 1.5. CHALLENGES AND OPPORTUNITIES 1.6. FUTURE OUTLOOK 2. MARKET INTRODUCTION 2.1. DEFINITION 2.2. SCOPE OF THE STUDY 2.2.1. RESEARCH OBJECTIVE 2.2.2. ASSUMPTION 2.2.3. LIMITATIONS 3. RESEARCH METHODOLOGY 3.1. OVERVIEW 3.2. DATA MINING 3.3. SECONDARY RESEARCH 3.4. PRIMARY RESEARCH 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS 3.5. FORECASTING MODEL 3.6. MARKET SIZE ESTIMATION 3.6.1. BOTTOM-UP APPROACH 3.6.2. TOP-DOWN APPROACH 3.7. DATA TRIANGULATION 3.8. VALIDATION 4. MARKET DYNAMICS 4.1. OVERVIEW 4.2. DRIVERS 4.3. RESTRAINTS 4.4. OPPORTUNITIES 5. MARKET FACTOR ANALYSIS 5.1. VALUE CHAIN ANALYSIS 5.2. PORTER'S FIVE FORCES ANALYSIS 5.2.1. BARGAINING POWER OF SUPPLIERS 5.2.2. BARGAINING POWER OF BUYERS 5.2.3. THREAT OF NEW ENTRANTS 5.2.4. THREAT OF SUBSTITUTES 5.2.5. INTENSITY OF RIVALRY 5.3. COVID-19 IMPACT ANALYSIS 5.3.1. MARKET IMPACT ANALYSIS 5.3.2. REGIONAL IMPACT 5.3.3. OPPORTUNITY AND THREAT ANALYSIS 6. BIOSIMILARS MARKET, BY TYPE (USD BILLION) 6.1. MONOCLONAL ANTIBODIES 6.2. INSULIN 6.3. ERYTHROPOIETIN 6.4. GROWTH HORMONES 7. BIOSIMILARS MARKET, BY APPLICATION (USD BILLION) 7.1. ONCOLOGY 7.2. DIABETES 7.3. AUTOIMMUNE DISEASES 7.4. CHRONIC INFLAMMATORY DISEASES 8. BIOSIMILARS MARKET, BY END USE (USD BILLION) 8.1. HOSPITALS 8.2. CLINICS 8.3. HOMECARE 8.4. RESEARCH INSTITUTIONS 9. BIOSIMILARS MARKET, BY MANUFACTURING PROCESS (USD BILLION) 9.1. RECOMBINANT DNA TECHNOLOGY 9.2. HYBRIDOMA TECHNOLOGY 9.3. TRANSGENIC TECHNOLOGY 10. BIOSIMILARS MARKET, BY REGIONAL (USD BILLION) 10.1. NORTH AMERICA 10.1.1. US 10.1.2. CANADA 10.2. EUROPE 10.2.1. GERMANY 10.2.2. UK 10.2.3. FRANCE 10.2.4. RUSSIA 10.2.5. ITALY 10.2.6. SPAIN 10.2.7. REST OF EUROPE 10.3. APAC 10.3.1. CHINA 10.3.2. INDIA 10.3.3. JAPAN 10.3.4. SOUTH KOREA 10.3.5. MALAYSIA 10.3.6. THAILAND 10.3.7. INDONESIA 10.3.8. REST OF APAC 10.4. SOUTH AMERICA 10.4.1. BRAZIL 10.4.2. MEXICO 10.4.3. ARGENTINA 10.4.4. REST OF SOUTH AMERICA 10.5. MEA 10.5.1. GCC COUNTRIES 10.5.2. SOUTH AFRICA 10.5.3. REST OF MEA 11. COMPETITIVE LANDSCAPE 11.1. OVERVIEW 11.2. COMPETITIVE ANALYSIS 11.3. MARKET SHARE ANALYSIS 11.4. MAJOR GROWTH STRATEGY IN THE BIOSIMILARS MARKET 11.5. COMPETITIVE BENCHMARKING 11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE BIOSIMILARS MARKET 11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES 11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT 11.7.2. MERGER & ACQUISITIONS 11.7.3. JOINT VENTURES 11.8. MAJOR PLAYERS FINANCIAL MATRIX 11.8.1. SALES AND OPERATING INCOME 11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2023 12. COMPANY PROFILES 12.1. ZYDUS CADILA 12.1.1. FINANCIAL OVERVIEW 12.1.2. PRODUCTS OFFERED 12.1.3. KEY DEVELOPMENTS 12.1.4. SWOT ANALYSIS 12.1.5. KEY STRATEGIES 12.2. ELI LILLY 12.2.1. FINANCIAL OVERVIEW 12.2.2. PRODUCTS OFFERED 12.2.3. KEY DEVELOPMENTS 12.2.4. SWOT ANALYSIS 12.2.5. KEY STRATEGIES 12.3. SAMSUNG BIOEPIS 12.3.1. FINANCIAL OVERVIEW 12.3.2. PRODUCTS OFFERED 12.3.3. KEY DEVELOPMENTS 12.3.4. SWOT ANALYSIS 12.3.5. KEY STRATEGIES 12.4. GSK 12.4.1. FINANCIAL OVERVIEW 12.4.2. PRODUCTS OFFERED 12.4.3. KEY DEVELOPMENTS 12.4.4. SWOT ANALYSIS 12.4.5. KEY STRATEGIES 12.5. ABBVIE 12.5.1. FINANCIAL OVERVIEW 12.5.2. PRODUCTS OFFERED 12.5.3. KEY DEVELOPMENTS 12.5.4. SWOT ANALYSIS 12.5.5. KEY STRATEGIES 12.6. BOEHRINGER INGELHEIM 12.6.1. FINANCIAL OVERVIEW 12.6.2. PRODUCTS OFFERED 12.6.3. KEY DEVELOPMENTS 12.6.4. SWOT ANALYSIS 12.6.5. KEY STRATEGIES 12.7. TEVA PHARMACEUTICAL INDUSTRIES 12.7.1. FINANCIAL OVERVIEW 12.7.2. PRODUCTS OFFERED 12.7.3. KEY DEVELOPMENTS 12.7.4. SWOT ANALYSIS 12.7.5. KEY STRATEGIES 12.8. CELLTRION 12.8.1. FINANCIAL OVERVIEW 12.8.2. PRODUCTS OFFERED 12.8.3. KEY DEVELOPMENTS 12.8.4. SWOT ANALYSIS 12.8.5. KEY STRATEGIES 12.9. FRESENIUS KABI 12.9.1. FINANCIAL OVERVIEW 12.9.2. PRODUCTS OFFERED 12.9.3. KEY DEVELOPMENTS 12.9.4. SWOT ANALYSIS 12.9.5. KEY STRATEGIES 12.10. AMGEN 12.10.1. FINANCIAL OVERVIEW 12.10.2. PRODUCTS OFFERED 12.10.3. KEY DEVELOPMENTS 12.10.4. SWOT ANALYSIS 12.10.5. KEY STRATEGIES 12.11. REDDY'S LABORATORIES 12.11.1. FINANCIAL OVERVIEW 12.11.2. PRODUCTS OFFERED 12.11.3. KEY DEVELOPMENTS 12.11.4. SWOT ANALYSIS 12.11.5. KEY STRATEGIES 12.12. MYLAN 12.12.1. FINANCIAL OVERVIEW 12.12.2. PRODUCTS OFFERED 12.12.3. KEY DEVELOPMENTS 12.12.4. SWOT ANALYSIS 12.12.5. KEY STRATEGIES 12.13. SANDOZ 12.13.1. FINANCIAL OVERVIEW 12.13.2. PRODUCTS OFFERED 12.13.3. KEY DEVELOPMENTS 12.13.4. SWOT ANALYSIS 12.13.5. KEY STRATEGIES 12.14. PFIZER 12.14.1. FINANCIAL OVERVIEW 12.14.2. PRODUCTS OFFERED 12.14.3. KEY DEVELOPMENTS 12.14.4. SWOT ANALYSIS 12.14.5. KEY STRATEGIES 12.15. NOVARTIS 12.15.1. FINANCIAL OVERVIEW 12.15.2. PRODUCTS OFFERED 12.15.3. KEY DEVELOPMENTS 12.15.4. SWOT ANALYSIS 12.15.5. KEY STRATEGIES 13. APPENDIX 13.1. REFERENCES 13.2. RELATED REPORTS
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Market Research Future社の医療分野での最新刊レポート
本レポートと同じKEY WORD(biosimilars)の最新刊レポート
よくあるご質問Market Research Future社はどのような調査会社ですか?マーケットリサーチフューチャー(Market Research Future)は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。 下記分野については、分野毎に専... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|